Polydatin Attenuates Cisplatin-Induced Acute Kidney Injury via SIRT6-Mediated Autophagy Activation

Zhen Li, Lu Zhou, Yiwei Du, Huirong Li, Lan Feng, Xiangnan Li, Xiao Han, and Hongbao Liu

Department of Nephrology, Tangdu Hospital, Air Force Military Medical University (Fourth Military Medical University), Xi’an 710038, China

Correspondence should be addressed to Hongbao Liu; xjsnlhb@fmmu.edu.cn

Received 7 June 2022; Revised 17 July 2022; Accepted 26 August 2022; Published 16 September 2022

Academic Editor: Dr Amira Badr

Copyright © 2022 Zhen Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the treatment of malignant tumors, the effectiveness of cisplatin (CP) is limited by its nephrotoxicity, leading to cisplatin-induced acute kidney injury (CP-AKI). Polydatin (PD) has been demonstrated to regulate autophagy in tumors, sepsis, and diabetes. We have recently confirmed that PD attenuated CP-AKI by inhibiting ferroptosis, but it is not clear whether PD can regulate autophagy to protect from CP-AKI. The purpose of this study was to investigate the effect of PD on autophagy in CP-treated HK-2 cells and CP-AKI mouse models, exploring the role of sirtuin 6 (SIRT6) upregulated by PD. In this study, the blocking of autophagy flux was observed in both CP-treated HK-2 cells in vitro and CP-AKI mouse models in vivo, whereas this blocking was reversed by PD, which was characterized by the increase of autophagy microtubule-associated protein light chain 3 II expression and autophagolysosome/autophagosome ratio and the decrease of p62 expression. Furthermore, PD also significantly increased the expression of SIRT6 in vivo and in vitro. The protective effect of PD manifested by the stimulating of autophagy flux, with the reducing of inflammatory response and oxidative stress, which included downregulation of tumor necrosis factor-α and interleukin-1β, decreased activity of myeloperoxidase and content of malondialdehyde, and increased activity of superoxide dismutase and level of glutathione, both in vivo and in vitro, was reversed by either inhibition of autophagy flux by chloroquine or downregulation of SIRT6 by OSS-128167. Taken together, the present findings provide the first evidence demonstrating that PD exhibited nephroprotective effects on CP-AKI by restoring SIRT6-mediated autophagy flux mechanisms.

1. Introduction

As the mainstay in the treatment of various types of tumors, the application of cisplatin (CP) is hindered by dose limitation due to its nephrotoxicity, such as acute kidney injury (AKI) in 20%-30% of patients [1]. However, so far, there is still a lack of effective drugs to treat Cis-AKI clinically. The pathogenesis of CP-induced AKI (CP-AKI) is complex and multifactorial, including autophagy, which has been proved to exert a nephroprotective role in experimental models of CP-AKI by using both pharmacological and genetic approaches in recent years [2]. Autophagy has always been regarded as a double-edged sword in tumor therapy [1, 3], so when targeting autophagy as a nephroprotective strategy in CP-AKI, its effect on tumors should be considered. Polydatin (PD, C_{20}H_{22}O_{8}), a glucoside of resveratrol, known as a natural active ingredient extracted from Polygonum cuspidatum Sieb. et Zucc., is used for both medication and food, which plays a multitarget protective role in AKI by antiapoptosis, anti-inflammation, antioxidative stress, antiferroptosis, and regulation of autophagy [4–12]. What is more, PD has also been proved to play an antitumor effect by inhibiting cell viability, migration, and invasion of different tumor cells [13–15]. PD has been clinically used to treat multiple diseases, showing its safety in human application [16–18], which suggests that it can be used as a promising alternative compound for treating CP-AKI in cancer patients.

In recent years, the relationship between PD and autophagy has attracted considerable attention in different diseases, including sepsis [5, 19, 20], ischemia-reperfusion...
(I/R) injury [21–23], diabetes [24, 25], atherosclerosis [26], Parkinson’s disease [27], and tumors [13, 28–30]. PD has also been verified to play a nephroprotective role by regulating autophagy in sepsis-induced AKI [5, 6] and diabetic nephropathy [25]. In our last study, PD can alleviate CP-AKI by inhibiting ferroptosis [4], but whether autophagy is involved in the nephroprotection of PD on CP-AKI has not been reported yet.

Sirtuin 6 (SIRT6) belongs to a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, which plays a protective role in different organ injuries by regulating autophagy [31]. Overexpression of SIRT6 can alleviate CP-AKI [32], but the relationship between SIRT6 and autophagy in CP-AKI remains a mystery. Recently, PD has been found to protect septic myocardial injury by promoting SIRT6-activated autophagy [19]. Our previous studies confirmed the renal protective effect of PD through antioxidative stress and antiferroptosis in I/R-induced AKI (I/R-AKI) and CP-AKI [4, 9, 11]. Based on the above evidence, we hypothesized that PD may attenuate CP-AKI through SIRT6-mediated autophagy.

Therefore, this study intends to investigate the correlation between autophagy and SIRT6 activation in the nephroprotection of PD in CP-AKI model both in vivo and in vitro, which may provide reliable evidence for the research and development of nephroprotective drugs in the clinical treatment of AKI.

2. Materials and Methods

2.1. Chemicals and Reagents. Cisplatin (CP, Cat. No. MB1055) and Polydlin (PD, Cat. No. MB5448) were purchased from Mecillun Biotech (Dalian, China). Chloroquine (CQ, Cat. No. C6628) was bought from Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO, Cat. No. D8371) was gained from Beijing Solarbio Science & Technology Co., Ltd. Ramapycin (RAP, AV-22989, Cat. No. S1039) and OSS-128167 (SIRT6-IN-1, Cat. No. S8627) were purchased from Salellect Chemicals (Houston, TX, United States). Dulbecco’s modified Eagle’s medium (DMEM, Cat. No. SH30243.01) was bought from Cytiva. Fetal bovine serum (FBS, Cat. No. IC-1905) was gained from InCellGenE LLC. Phosphate-buffered saline (PBS, Cat. No. G4202), fluorescein (FITC) TUNEL cell apoptosis detection kit (Cat. No. G1501), and DAPI fluorescence staining kit (Cat. No. G1012) were purchased from the Wuhan Servicebio Technology Co Ltd. Additionally, myeloperoxidase (MPO, Cat. No. A044-1-1), malondialdehyde (MDA, Cat. No. A003-1-2), superoxide dismutase (SOD, Cat. No. A001-3-2), and glutathione (GSH, Cat. No. A006-2-1) test kits were offered by the Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

2.2. Cell Culture and Treatment. Human proximal tubular epithelial cells (HK-2 cells), obtained from the China Center for Type Culture Collection (GDC0152, Wuhan, China), were cultured in DMEM medium containing 10% FBS and 100 units of antibiotics (streptomycin and penicillin) per ml at 37°C. The exponentially growing HK-2 cells were inoculated in six-well culture plate with 2 to 4 × 10^5 cells/well and cultured for 1 day before each experiment. After treating HK-2 cells with CP in dose gradient (5 μM, 10 μM, and 20 μM) and time gradient (6 h, 12 h, 18 h, and 24 h), according to the protein expression of LC3 II and p62, the cells treated with CP in a dose of 20 μM for 24 h were determined for the follow-up experiment. To investigate the effect of CP on autophagy of HK-2 cells, the cells were pretreated with CQ (20 μM) or RAP (50 nM) for 4 h before induction with CP (20 μM) for 24 h. To evaluate the role of PD on autophagy, HK-2 cells were pretreated with PD in a dose gradient (20 μM, 40 μM, and 80 μM) for 2 h before induction with CP (20 μM) for 24 h. According to the change of the protein expression of LC3 II and p62, and cell apoptosis rate in HK-2 cells, a 40 μM dose of PD was determined as the best dose. Therefore, the following experiments divided the cells into four groups: control group, CP (20 μM) group, CP + PD (40 μM) group, and CP + PD + CQ (20 μM) group. To clarify the role of SRIT6 in PD on the autophagy flux of CP-treated HK-2 cells, OSS-128167 (50 μM), a SIRT6 selective inhibitor, was used instead of CQ to pre-treat the cells for 0.5 h before induction with CP (20 μM) for 24 h. Experimental design in vitro is shown in Figure 1.

2.3. Western Blot (WB) Analysis. Equal amounts of protein from both cultured HK-2 cells and renal tissue lysates were loaded and separated using 10% sodium dodecyl sulfate (SDS) polyacrylamide gel and transferred to a polyvinylidene fluoride (PVDF) membrane. The membranes were blocked in 5% nonfat dry milk (diluted in TBST with 0.1% Tween-20) for 1 h at room temperature. The membrane was incubated overnight at 4°C of light chain 3A/B (LC3A/B, 1:1000, Cell Signaling Technology, Cat. No. #4108), SIRT6 (1:1000, Cell Signaling Technology, Cat. No. #12486), sequestosome 1 (SQSTM1/p62, 1:10000, Abcam, Cat. No. ab109012), or GAPDH (1:1000, Servicebio Technology, Cat. No. GB12002) antibodies which were appropriately diluted in 1 × TBST containing 5% nonfat dry milk, followed by peroxidase-conjugated secondary antibody. The immune complexes were visualized with appropriate horse-radish peroxidase-conjugated secondary antibody (1:2000, Cat. No: SA-10010 and SA-10011, InCellGenE LLC) and enhanced chemiluminescence system (Cat. No. IC-5008-100, InCellGenE LLC).

2.4. Transfection of mRFP-GFP-LC3 Adenovirus. Cells were transfected with monomeric red fluorescent protein (mRFP)-green fluorescent protein (GFP)-LC3 adenovirus (Cat. No. HB-AP2100001, Hanheng Biotechnology, Shanghai, China) supplemented with half the volume of medium after 4 h and replaced with fresh medium after 6 h to continue the culture. Different groups were treated with corresponding drugs, and the cells were photographed under a confocal laser scanning microscope (CLSM) 24 h after adding CP.

2.5. Apoptosis Assay. Apoptosis was detected using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Cat. No. 556547, BD Pharmingen, USA) following the manufacturer’s instructions. 5 μl Annexin V-FITC and 2 μl propidium iodide (PI) were added into the
single-cell suspension, which was incubated in the dark for 15 min, and then the cells were analyzed by fluorescence-activated cell sorting (FACS, Beckman, USA).

2.6. Animals and Experimental Protocol. Male C57BL/6 mice (8-10 weeks old) were purchased from the Animal Center of Air Force Military Medical University (Fourth Military Medical University). All animal experiments were conducted in strict accordance with the Guidelines of Health and guidelines for use, and were permitted by the Animal Welfare and Ethics Institution of the Tangdu Hospital, Air Force Military Medical University (IACUC approval number 202003-100). According to previous reports from us and other authors [2, 4], a single intraperitoneal injection of CP at a dose of 20 mg/kg is sufficient to induce AKI in mice. To select the best dose of PD in CP-AKI mice, the animals were randomly divided into five experimental groups (n = 6-8 each) as follows: control (equivalent saline containing 1% DMSO, i.p.) group, CP (20 mg/kg dissolved in saline, i.p.) group, CP + PD low-dose (PD-L, 20 mg/kg dissolved in 1% DMSO, i.p.) group, CP + PD middle-dose (PD-M, 40 mg/kg dissolved in 1% DMSO, i.p.) group, and CP + PD high-dose (PD-H, 80 mg/kg dissolved in 1% DMSO, i.p.) group [11]. To estimate the effect of autophagy flux blocking on renal protection of PD in CP-AKI mice, the animals were divided into the following four groups (n = 6-8 each): control group, CP (20 mg/kg, i.p.) group, CP + PD (40 mg/kg, i.p.) group, and CP + PD + CQ (60 mg/kg, i.p.) group [33]. To evaluate the role of SIRT6 in PD on the autophagy flux in CP-AKI mice, OSS-128167 (50 mg/kg, i.p.) [34] was used to replace CQ in the previous groups (n = 6-8 each). Mice were injected with CP once; PD or CQ was given 1 h before and 24 h after CP. OSS-128167 was administered only 1 h before CP; RAP: rapamycin (in vitro: 50 nM, 4 h before induction with CP; in vivo: 50 mg/kg, i.p., 1 h before CP); SIRT6: sirtuin 6; WB: Western blot; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); CLSM: confocal laser scanning microscope; FACS: fluorescence-activated cell sorting; BUN: blood urea nitrogen; Scr: serum creatinine; H&E: hematoxylin-eosin; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling; TNF-α: tumor necrosis factor-α; IL-1β: interleukin-1β; MPO: myeloperoxidase; MDA: malondialdehyde, SOD: superoxide dismutase; GSH: glutathione.
of kidney weight (g) and 50 mmol/l phosphate buffer (pH 7.4) volume (ml) = 1: 9. Centrifuge at 1500 g for 20 min and collect the supernatant as the sample to be tested immediately.

2.10. Enzyme-Linked Immunosorbent Assay (ELISA). The levels of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in renal tissue homogenate were evaluated with a commercially available ELISA kit (R&D Systems, USA), according to the manufacturer’s recommendation. All standards and samples were measured in duplicate.

2.11. Measurement of Renal Oxidative Indexes. The kidney supernatant was used to measure the activity of MPO and SOD, and the content of MDA and GSH followed the commercial kit instructions by using a spectrophotometer (Spectrophotometer DU640, Beckman Coulter, Fullerton, CA). All levels were expressed as U/mg protein, nmol/mg protein, or mg/g protein, respectively.

2.12. Renal Histopathology and Terminal Deoxynucleotidyl Transferase dUTP Nick-End Labeling (TUNEL) Assay. Fresh kidney tissue was rinsed with frozen stroke physiological saline, fixed in 10% neutral buffered formalin overnight, embedded in paraffin, and cut into 4-μm-thick sections for hematoxylin-eosin (H&E) staining and TUNEL fluorescent staining according to the manufacturer’s instructions. Renal tubular epithelial cells with the following histopathological changes were considered injured: loss of brush border, tubular dilation and disruption, cast formation, and cell lysis. The kidney tissue damage was performed by renal pathologists in a blinded fashion and scored by calculating the percentage of damaged tubules: 0 none; 1, <25%; 2, 25-50%; 3, 50-75%; and 4, >75%. The scores of at least 10 randomly selected areas per mouse kidney were averaged and used as the scores of the individual mouse kidneys.

2.13. Statistical Analysis. All data are presented as mean ± standard deviation (SD) of at least three independent experiments. Statistical analysis of data was performed with SPSS 19, and P values were determined using Student’s t-test and one-way analysis of variance (ANOVA) for two independent samples. Immunofluorescence and grayscale analysis of western blot bands were performed semiquantitative analysis using ImageJ. P < 0.05 was statistically significant.

3. Results

3.1. Autophagy Flux Was Restained in Cisplatin-Treated HK-2 Cells. Autophagy flux detection is considered as the “gold standard” to evaluate autophagy level [35], so we analyzed the effect of CP on the expression of autophagy-related genes LC3 and p62 in HK-2 cells. The results of western blot showed that CP led to the upregulation of the LC3 II and p62 protein expression in HK-2 cells in a dose-dependent manner, and this change was most significant at the dose of 20 μM CP (Figures 2(a) and 2(b)). Therefore, we chose 20 μM CP to treat the cells and observed the effects of different culture times (6, 12, 18, and 24 h) on the autophagy flux of HK-2 cells. Similarly, LC3 II and p62 expression were also increased in a time-dependent manner by CP, and this change was most significant at 24 h of culture, about 3.48- and 4.17-fold as compared to the control group (Figures 2(c) and 2(d)). These findings indicated that the autophagy degradation of HK-2 cells was interfered by CP, and the subsequent experiments in this study were carried out when the HK-2 cells were treated with CP at a dose of 20 μM for 24 h. Then, we introduced CQ (an autophagy inhibitor) or RAP (an autophagy activator) into CP-treated HK-2 cells and evaluated the changes of autophagy flux by the above protein expression assay and mRFP-GFP-LC3 transfection method. WB results showed that the LC3 II and p62 expression increased by CP were promoted by CQ and decreased by RAP (Figures 2(e) and 2(f)). mRFP-GFP-LC3 is a widely used autophagic indicator with a yellow LC3 signal when in the autophagosome (with both GFP and RFP signals) and a red LC3 signal when in the autophagolysosome due to the acidic milieu that quenches GFP signal. As shown in Figures 2(g) and 2(h), compared with the control, CP induced the increase of yellow puncta (named YFP), suggesting the blockage of autophagy flux from the autophagosome to the autophagolysosome. Furthermore, the CP-induced YFP/RFP ratio was further aggravated by CQ and reversed by RAP (Figures 2(g) and 2(h)). Concomitantly, the FACS analysis of Annexin V and PI staining showed that the increased apoptosis induced by CP was worsened by CQ and alleviated by RAP (Figures 2(i) and 2(j)). These findings suggested that CP-induced autophagy flux blocking had adverse effects on HK-2 cells.

3.2. PD Attenuated Cisplatin-Induced Apoptosis of HK-2 Cells by Restoring the Autophagy Flux. Although it has been proved that PD plays a renal protective role through activating autophagy in sepsis-induced AKI and diabetic nephropathy, the relationship between PD and autophagy in CP-AKI remains unclear. First, we evaluated the effects of different doses of PD (20 μM, 40 μM, and 80 μM) on the autophagy flux in CP-treated HK-2 cells. WB results showed that, compared with the control, CP (20 μM) significantly induced the increase of LC3 II and p62 expression (Figures 3(a) and 3(b)). PD increased the lipid conjugation of free LC3 I to the autophagic membrane-associated LC3 II and decreased the expression of p62 in a dose-dependent manner, with 40 μM and 80 μM being the most significant (Figures 3(a) and 3(b)). Concomitantly, 40 μM and 80 μM doses of PD significantly reduced CP-induced cell apoptosis compared with 20 μM PD (Figure 3(c)), so we chose 40 μM dose of PD for the follow-up experiment. To determine whether PD regulates autophagosome formation or autophagy flux, CQ, known as a lysosomal inhibitor, has been used in the experiments. As expected, in CP-treated HK-2 cells, compared with PD alone, PD combined with CQ (20 μM) increased the expression of LC3 II and p62 (Figures 3(d) and 3(e)). Similarly, the mRFP-GFP-LC3 transfection method showed that compared with CP alone, PD significantly induced the increased red puncta, but PD combined with CQ significantly increased the yellow puncta (with both GFP and RFP signals), suggesting that PD enhanced not
Figure 2: Continued.
Figure 2: Continued.
FACS-based Annexin V/PI apoptosis assay. ∗ survival analysis of HK-2 cells treated CP (20 μM) showed that autophagosome (yellow dots in merged images) and autophagolysosome (red only dots in merged images) were shown. (i and j) In vitro, we further evaluated the effect of PD on autophagyflux in CP-treated HK-2 cells, according to the decrease of red bolts and the increase of yellow bolts (Figures 4(c) and 4(d)). Furthermore, the apoptosis of CP-treated cells improved by PD was also reversed by OSS-128167 (Figures 4(e) and 4(f)). These data suggested that the inhibition of SIRT6 reversed the recovery of PD on CP-induced autophagy flux in CP-treated HK-2 cells, according to the decrease of red bolts and the increase of yellow bolts (Figures 4(c) and 4(d)). Furthermore, the apoptosis of CP-treated cells improved by PD was also reversed by OSS-128167 (Figures 4(e) and 4(f)). These data suggested that the inhibition of SIRT6 reversed the recovery of PD on CP-induced autophagy flux blocking in HK-2 cells.

3.4. PD Can Improve the Renal Function and Autophagy Flux Blocking of CP-AKI Animals. Based on the protective effect of PD on the autophagy flux of CP-treated cells in vitro, we further evaluated the effect of PD on autophagy flux blocking in cultured HK-2 cells with different doses of CP (5 μM, 10 μM, and 20 μM) for 24 h, and the semiquantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (a and b) Western blot of LC3 and p62 in HK-2 cells treated with 20 μM CP at different time (6 h, 12 h, 18 h, and 24 h), and the semiquantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (c and d) Western blot of LC3 and p62 in HK-2 cells treated with 20 μM CP or RAP (50 nM), and the semiquantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (g and h) CLSM image of HK-2 cells expressing mRFP-GFP-LC3. HK-2 cells transfected with adenovirus harboring tandem fluorescent mRFP-GFP-LC3 for 24 h were subjected to CP (20 μM) or RAP (50 nM), and nuclei were labeled with DAPI (blue), the GFP dots were green, and the mRFP dots were red. Scale bar = 10 μm. The semiquantitative analysis of autophagosome (yellow dots in merged images) and autophagolysosome (red only dots in merged images) were shown. (i and j) In vitro survival analysis of HK-2 cells treated CP (20 μM) combined with CQ (20 μM) or RAP (50 nM). The nuclei were labeled with DAPI (blue), the GFP dots were green, and the mRFP dots were red. Scale bar = 10 μm. The semiquantitative analysis of autophagosome (yellow dots in merged images) and autophagolysosome (red only dots in merged images) were shown. (i and j) In vitro survival analysis of HK-2 cells treated CP (20 μM) supplemented with CQ (20 μM) or RAP (50 nM), and bar graph described from the FACS-based Annexin V/PI apoptosis assay. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. CP (n = 6).

CP: cisplatin; CQ: chloroquine; RAP: rapamycin; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); PI: propidium iodide; CLSM: confocal laser scanning microscope; FACS: fluorescence-activated cell sorting.
Figure 3: Continued.
Figure 3: Continued.
in CP-AKI mice in vivo. To this end, different doses of PD (PD-L:20 mg/kg; PD-M: 40 mg/kg; PD-H: 80 mg/kg) were intra-peritoneally injected 1 h before CP injection and then re-injected 24 h after CP injection. The CP-AKI mice were killed 48 h after CP administration and then re-injected 24 h after CP administration (Figure 6(a)). As shown in Figures 6(b) and 6(c), in CP-AKI mice, the PD-increased degradation of p62 (a selective substrate of autophagy) was inhibited by CQ, and the expression of LC3 II in the kidneys of CP-AKI mice was increased, which was abolished by combined CQ treatment (Figure 6(e)). As shown in Figures 6(f), BUN (Figure 6(f)), Scr (Figure 6(g)), renal tubular damage (Figures 6(h) and 6(j)), and cell apoptosis (Figures 6(i) and 6(k), Supplementary Table 1(b)) in CP-AKI mice were reversed by CQ.

In AKI, besides apoptosis, the mutual crosstalk of inflammation and oxidative stress has also been confirmed [36]. CP-AKI mice had significantly increased TNF-α (Figures 6(l) and IL-1β (Figure 6(m)) levels in the kidney, compared to the control group. PD reduced the levels of TNF-α and IL-1β in the kidneys of CP-AKI mice, which was abolished by combined CQ treatment (Figures 6(l) and 6(m)). To validate the potential effect of PD on antioxidative stress in CP-AKI, we detected the activity of MPO (Figure 6(n)) and SOD (Figure 6(p)) and the contents of MDA (Figure 6(o)) and GSH (Figure 6(q)) in the kidneys, respectively. Compared with the control mice, the MPO activity and MDA content were significantly increased in CP-AKI mice, which were reversed in PD group, but the beneficial effect of PD was abolished by CQ (Figures 6(n) and 6(o)). Likewise, CQ abolished the

3.5. Chloroquine Eliminated the Nephroprotective Effect of PD on CP-AKI Mice in Terms of Recovery of Damaged Autophagy Flux, Anti-inflammation, and Antioxidative Stress. The inhibitory effect of CQ on renal autophagy flux in CP-AKI mice in vivo has been widely confirmed [3]. To figure out the role of autophagy flux in the nephroprotection of PD, PD (40 mg/kg) and CQ (60 mg/kg) were intraperitoneally injected into CP-AKI mice 1 h before CP administration and then re-injected 24 h after CP administration. Therefore, the subsequent experiments in this study were all performed following this treatment.

Figure 3: PD attenuated cisplatin-induced apoptosis of HK-2 cells by restoring the autophagy flux. (a and b) Western blot of LC3 and p62 in CP (20 μM)-treated HK-2 cells supplemented with different doses of PD (20 μM, 40 μM, and 80 μM), and the semiquantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (c) In vitro survival analysis of HK-2 cells treated CP (20 μM) supplemented with different doses of PD (20 μM, 40 μM, and 80 μM), and bar graph described from the FACS-based Annexin V/PI apoptosis assay. (d and e) Western blot of LC3 and p62 in CP (20 μM)-treated HK-2 cells supplemented with PD (40 μM) or PD plus CQ (20 μM), and the semiquantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (f and g) CLSM image of HK-2 cells expressing mRFP-GFP-LC3. HK-2 cells transfected with adenovirus harboring tandem fluorescent mRFP-GFP-LC3 for 24 h were subjected to CP (20 μM) combined with PD (40 μM) and CQ (20 μM). The nuclei were labeled with DAPI (blue), the GFP dots were green, and the mRFP dots were red. Scale bar = 10 μm. The semiquantitative analysis of autophagosome (yellow dots in merged images) and autophagolysosome (red only dots in merged images) were shown. (h and i) In vitro survival analysis of CP (20 μM)-treated HK-2 cells supplemented with PD (40 μM) or PD plus CQ (20 μM), and bar graph described from the FACS-based Annexin V/PI apoptosis assay. *P<0.05, **P<0.01, and ***P<0.001 vs. control; †P<0.05, ‡P<0.01, and §§P<0.001 vs. CP. **P<0.05, $$$P<0.01, and $$$P<0.001 vs. CP + PD40 (40 μM) (n = 6). CP: cisplatin; PD: polydatin; CQ: chloroquine; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); PI: propidium iodide; CLSM: confocal laser scanning microscope; FACS: fluorescence-activated cell sorting.

Oxidative Medicine and Cellular Longevity
Figure 4: Continued.
antioxidant effect of PD in CP-AKI mice, showing the decrease of SOD activity and GSH content (Figures 6(p) and 6(q)). These results suggested that the nephroprotective effect of PD on CP-AKI mice was at least partly related to the recovery of autophagy flux.

3.6. Inhibition of SIRT6 by OSS-128167 Eliminated the Nephroprotective Effect of PD on CP-AKI Mice in Terms of Recovery of Damaged Autophagy Flux, Anti-inflammation, and Antioxidative Stress. To further evaluate the effect of SIRT6 on the nephroprotection of PD (40 mg/kg) in CP-AKI mice in vivo, the mice were orally administered OSS-128167 (50 mg/kg) through gavage 1 h before CP (20 mg/kg) injection (Figure 7(a)). WB results showed that PD significantly promoted SIRT6 expression in CP-AKI mice, and this effect was clearly inhibited by OSS-128167 (Figures 7(b) and 7(c)). Meanwhile, OSS-128167 also clearly abolished the recovery effect of PD on the autophagy flux in the kidneys of CP-AKI mice (Figures 7(b) and 7(c)). In addition, OSS-128167 also diminished the protective effect of PD on body weight (Figure 7(d)), kidney index (Figure 7(e)), BUN (Figure 7(f)), Scr (Figure 7(g)), renal tubular damage (Figures 7(h) and 7(j)), and cell apoptosis (Figures 7(i) and 7(k), Supplementary Table 1(c)) in CP-AKI mice. Furthermore, OSS-128167 also significantly inhibited the anti-inflammatory and antioxidative stress effects of PD in CP-AKI mice, which showed increase in the levels of TNF-α (Figure 7(l)) and IL-1β (Figure 7(m)), the MPO activity (Figure 7(n)) and MDA content (Figure 7(o)), and decrease in the SOD activity (Figure 7(p)) and GSH content (Figure 7(q)). These data suggested that the protective effect of PD on impaired autophagy flux and renal function in CP-AKI mice was at least partially related to the activation of SIRT6.

4. Discussion

On account of its nephrotoxicity, including AKI, CP is limited in the treatment of malignant tumors [1]. It has been proved that autophagy flux blocking is one of the mechanisms of CP nephrotoxicity, but so far there is no specific drug for AKI. We have recently confirmed the nephroprotective effect of PD in CP-AKI [4], but the role of PD in the damaged autophagy flux has not been reported in CP-AKI mice. In this study, the correlation between autophagy flux and SIRT6 in the nephroprotection of PD was investigated in in vivo and in vitro models of CP-AKI, with the following highlights: (1) It was first confirmed that PD could alleviate CP-AKI by restoring autophagy flux; (2) it was confirmed for the first time that the inhibition of SIRT6 pathway reverses the recovery effect of PD on CP-blocked autophagy flux, suggesting the potential effect of SIRT6-mediated autophagy flux on the nephroprotection of PD in CP-AKI.

Autophagy is a lysosomal degradation pathway, which acts a nephroprotective role under normal physiological conditions and when the kidney is exposed to injuries or toxins, such as CP [2]. The pharmacologic and genetic inhibition and activation of autophagy can increase and reduce renal tubular injury during CP treatment, respectively [2]. This study showed that the autophagy flux was blocked in CP-treated HK-2 cells and CP-AKI mice, which was characterized by the increase of LC3 II and p62 in WB, and the decrease of autophagolysosome/autophagosome ratio in mRFP-GFP confocal test, which were consistent with other studies [37, 38]. The autophagy flux blocking and cell apoptosis induced by CP in a dose-dependent and time-dependent manner were further aggravated by CQ and alleviated by RAP, suggesting that autophagy flux blocking may be associated with CP nephrotoxicity.
Polydatin, a natural polyphenol plant extract, has been proved to have a nephroprotective effect in different AKI and chronic kidney disease (CKD) models [21]. Deng et al. proved an important role of PD in autophagy by activating SIRT1-mediated Beclin1 deacetylation in sepsis-induced AKI [5]. Gu et al. showed that PD ameliorated autophagy imbalance in an mTORC1-dependent manner during fructose-induced podocyte injury [25]. The renal protective
**MPO (n), MDA (o), SOD (p), and GSH (q).**

Cytokines including TNF-α:

- Inhibition of autophagy by CQ abolished the nephroprotective effect of PD on CP-AKI mice. (a) Mice pretreated with PD (40 mg/kg) or PD plus CQ (60 mg/kg) were administered with intraperitoneal injections of CP (20 mg/kg), and either PD or PD plus CQ was intraperitoneally reinjected at 24 h after CP injection. They were executed 48 h after the CP injection. (b and c) Western blot of LC3 and p62 in kidneys of CP-AKI mice that received PD (40 mg/kg), PD plus CQ (60 mg/kg), or vehicle (saline with 1% DMSO), and the semi-quantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (d-g) Body weight changes, kidney index, BUN, and Scr were measured at 48 h after CP injection. (h and j) Histopathology analysis of the kidneys in CP-AKI mice was performed by H&E staining, and the tubular damage was graded. Scale bar = 50 μm. (i and k) Representative TUNEL-stained sections of the kidney. Scale bar = 50 μm. (l and m) Histologic levels of typical inflammatory cytokines including TNF-α and IL-1β in the kidneys were measured by ELISA. (n-q) Kidney tissue homogenates were evaluated by the assays of MPO (n), MDA (o), SOD (p), and GSH (q).

*(P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; ^P < 0.05, ^^P < 0.01, and ^^^P < 0.001 vs. CP; \(^P < 0.05, ^{\times}P < 0.01, \) and \(^{\times\times}P < 0.001\) vs. CP + PD. CP: cisplatin; PD: polydatin; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); BUN: blood urea nitrogen; Scr: serum creatinine; HE: hematoxylin-eosin; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling; ELISA: enzyme-linked immunosorbent assay; TNF-α: tumor necrosis factor-α; IL-1β: interleukin-1β; MPO: myeloperoxidase; MDA: malondialdehyde; SOD: superoxide dismutase; GSH: glutathione.*

---

**Figure 6: Inhibition of autophagy by CQ abolished the nephroprotective effect of PD on CP-AKI mice.**

(a) Mice pretreated with PD (40 mg/kg) or PD plus CQ (60 mg/kg) were administered with intraperitoneal injections of CP (20 mg/kg), and either PD or PD plus CQ was intraperitoneally reinjected at 24 h after CP injection. They were executed 48 h after the CP injection. (b and c) Western blot of LC3 and p62 in kidneys of CP-AKI mice that received PD (40 mg/kg), PD plus CQ (60 mg/kg), or vehicle (saline with 1% DMSO), and the semi-quantitative analysis of LC3 II/GAPDH and p62/GAPDH were shown. (d-g) Body weight changes, kidney index, BUN, and Scr were measured at 48 h after CP injection. (h and j) Histopathology analysis of the kidneys in CP-AKI mice was performed by H&E staining, and the tubular damage was graded. Scale bar = 50 μm. (i and k) Representative TUNEL-stained sections of the kidney. Scale bar = 50 μm. (l and m) Histologic levels of typical inflammatory cytokines including TNF-α and IL-1β in the kidneys were measured by ELISA. (n-q) Kidney tissue homogenates were evaluated by the assays of MPO (n), MDA (o), SOD (p), and GSH (q).}

*(P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; ^P < 0.05, ^^P < 0.01, and ^^^P < 0.001 vs. CP; \(^P < 0.05, ^{\times}P < 0.01, \) and \(^{\times\times}P < 0.001\) vs. CP + PD. CP: cisplatin; PD: polydatin; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); BUN: blood urea nitrogen; Scr: serum creatinine; HE: hematoxylin-eosin; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling; ELISA: enzyme-linked immunosorbent assay; TNF-α: tumor necrosis factor-α; IL-1β: interleukin-1β; MPO: myeloperoxidase; MDA: malondialdehyde; SOD: superoxide dismutase; GSH: glutathione.*

---

**Table:**

| Comparison | Control | CP | PD | CQ |
|------------|---------|----|----|----|
| Kidney index | 100 | 150 | 200 |
| BUN (mg/dl) | 50 | 100 | 150 |
| Scr (mg/dl) | N.S. | N.S. | N.S. |
| TUNEL+ nuclei (mm²) | N.S. | N.S. | N.S. |
| LC3 II | N.S. | N.S. | N.S. |
| p62 | N.S. | N.S. | N.S. |

*(P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; ^P < 0.05, ^^P < 0.01, and ^^^P < 0.001 vs. CP; \(^P < 0.05, ^{\times}P < 0.01, \) and \(^{\times\times}P < 0.001\) vs. CP + PD. CP: cisplatin; PD: polydatin; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); BUN: blood urea nitrogen; Scr: serum creatinine; HE: hematoxylin-eosin; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling; ELISA: enzyme-linked immunosorbent assay; TNF-α: tumor necrosis factor-α; IL-1β: interleukin-1β; MPO: myeloperoxidase; MDA: malondialdehyde; SOD: superoxide dismutase; GSH: glutathione.*
Figure 7: Inhibition of SIRT6 by OSS-128167 reversed the recovery of damaged autophagy flux and renal function of PD on CP-AKI mice. (a) Mice pretreated with PD (40 mg/kg) or PD plus OSS-128167 (50 mg/kg) were administered with intraperitoneal injections of CP (20 mg/kg), and PD was intraperitoneally reinjected at 24 h after CP injection. They were executed 48 h after the CP injection. (b and c) Western blot of SIRT6, LC3, and p62 in the kidneys of CP-AKI mice that received PD (40 mg/kg), PD plus OSS-128167 (50 mg/kg), or vehicle (saline with 1% DMSO), and the semiquantitative analysis of SIRT6/GAPDH, LC3 II/GAPDH, and p62/GAPDH were shown. (d–g) Body weight changes, kidney index, BUN, and Scr were measured at 48 h after CP injection. (h and j) Histopathology analysis of the kidneys in CP-AKI mice that received PD (40 mg/kg), PD plus OSS-128167 (50 mg/kg), or vehicle (saline with 1% DMSO), and the tubular damage was graded. Scale bar = 50 μm. (i and k) Representative TUNEL-stained sections of the kidney. Scale bar = 50 μm. (l and m) Histologic levels of typical inflammatory cytokines including TNF-α and IL-1β in the kidneys were measured by ELISA. (n–q) Kidney tissue homogenates were evaluated by the assays of MPO (n), MDA (o), SOD (p), and GSH (q). *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control; †P < 0.05, ‡P < 0.01, and §§P < 0.001 vs. CP; ††P < 0.05, †††P < 0.01, and ‡‡‡P < 0.001 vs. CP + PD. CP: cisplatin; PD: polydatin; OSS: OSS-128167; SIRT6: sirtuin 6; LC3: autophagy microtubule-associated protein light chain 3; p62: sequestosome 1 (SQSTM1); BUN: blood urea nitrogen; Scr: serum creatinine; HE: hematoxylin-eosin; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling; ELISA: enzyme-linked immunosorbent assay; TNF-α: tumor necrosis factor-α; IL-1β: interleukin-1β; MPO: myeloperoxidase; MDA: malondialdehyde; SOD: superoxide dismutase; GSH: glutathione.

**Oxidative Medicine and Cellular Longevity**
The effect of PD in CP-AKI has recently been confirmed by our research team [4], but it is not clear whether PD can resist CP nephrotoxicity by regulating autophagy. The results of this study clearly showed that PD can restore CP-induced autophagy flux blocking in both CP-treated HK-2 cells in vitro and CP-AKI animals in vivo, which were manifested by the increase in LC3 II and autophagolysosome/autophagosome ratio, and the decrease in p62 accumulation; however, this effect was blocked by CQ. Concomitantly, renal protective effects of PD on CP-AKI, including antia-poptosis, anti-inflammation, and antioxidative stress, were also reversed by CQ, indicating that PD could at least partially protect mice against CP-AKI by restoring autophagy flux.

Cisplatin can cause multiple forms of cellular stress, such as oxidative stress, endoplasmic reticulum stress, mitochondrial damage, and mitophagy, which may be related to autophagy activation in CP-AKI [2]. It has been widely reported the role of energy signaling pathways mediated by mTOR, AMPK, and NAD$^+$ metabolism in the regulation of autophagy in CP nephrotoxicity [1]. Sirtuin 6 (SIRT6) belongs to NAD$^+$-dependent deacetylase, which is widely expressed in mammalian organs, and regulates multiple biological processes, including inflammatory response, oxidative stress, telomere homeostasis, and autophagy [31]. The protective effect of SIRT6 activating autophagy has been proved in different organ injuries, including I/R injury [39–41], diabetes [42–45], and sepsis [19, 46, 47]. Several studies have recently demonstrated the renal protective effect of SIRT6-induced autophagy in sepsis-induced AKI [47], hypertensive cardiorenal injury [48], podocyte injury [45], and cadmium-induced renal damage [49], respectively. Li et al. [32] confirmed that overexpression of SIRT6 attenuated CP-AKI by inhibiting extracellular signal-regulated kinase 1/2 signaling; Fan et al. [50, 51] confirmed that isoorientin and daphnetin can alleviate CP-AKI through antioxidative stress and antiapoptosis via activating the SIRT1/SIRT6/nuclear factor erythroid 2-related factor 2 pathway, but the relationship between SIRT6 and autophagy has not been reported in CP-AKI. A recent report shows that PD protects against septic myocardial injury by activating SIRT6-mediated autophagy [19]. Therefore, based on the recovery effect of PD on autophagy flux blocking in CP-AKI confirmed in this study, we further evaluated whether SIRT6 was involved. As expected, in the CP-AKI models in vivo and in vitro, OSS-128167, an inhibitor of SIRT6, not only inhibited SIRT6 expression promoted by PD, but also blocked the role of PD in the recovery of autophagy flux. Meanwhile, the inhibition of SIRT6 also weakened the renal protective effects of PD on CP-AKI, including antia-poptosis,
antii-inflammation, and antioxidative stress, which suggested that PD was at least partially protected from CP-AKI through the SIRT6-mediated activation of autophagy.

Autophagy is protective during CP-AKI, but it is considered as a double-edged sword in cancer therapy [1, 3]. The strategy of targeting autophagy in CP chemotherapy must consider the effects on both healthy and tumorous tissues, including the kidneys. Besides the protective effect on different organ injuries, the antitumor role of PD through different pathological effects including autophagy has also been confirmed [5, 6]. Clinically, PD has been used to treat patients with chronic alcoholism [16], irritable bowel syndrome [17], and interstitial cystitis/bladder pain syndrome [18]. Surprisingly, PD has recently been proposed as a potential natural active drug for the treatment of coronavirus disease 2019 [52–57]. All these evidences suggest that PD may be a promising option for patients with AKI during CP chemotherapy. It is imperative to further explore the mechanism of PD in AKI and CKD, including autophagy.

5. Conclusions
Collectively, our study demonstrated for the first time that PD boosts autophagy flux through SIRT6 upregulation and protects renal tubular epithelial cells from oxidative stress, inflammatory response, and apoptosis, thus alleviating cisplatin-induced AKI (Figure 8). PD seems a promising inducer for restoration of autophagy flux for AKI. Furthermore, PD could be considered as a renoprotective natural compound in cisplatin-induced AKI, although further studies are required to confirm its beneficial effects in CKD development after CP chemotherapy.

Abbreviations
AKI: Acute kidney injury
BUN: Blood urea nitrogen
Cis-AKI: Cisplatin-induced acute kidney injury
CKD: Chronic kidney disease
CLSM: Confocal laser scanning microscope
CQ: Chloroquine
ELISA: Enzyme-linked immunosorbent assay
FACS: Fluorescence-activated cell sorting
GSH: Glutathione
IL-1β: Interleukin-1β
I/R: Ischemia/reperfusion
I/R-AKI: Ischemia/reperfusion-induced acute kidney injury
LC-3: Autophagy microtubule-associated protein light chain 3
MDA: Malondialdehyde
MPO: Myeloperoxidase
NAD+: Nicotinamide adenine dinucleotide
PD: Polydatin
PD-H: High-dose polydatin
PD-L: Low-dose polydatin
PD-M: Moderate-dose polydatin
PI: Propidium iodide
p62: Sequestosome 1 (SQSTM1)
RAP: Rapamycin
Scr: Serum creatinine
SIRT6: Sirtuin 6
SOD: Superoxide dismutase
TNF-α: Tumor necrosis factor-α
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick-end labeling
WB: Western blot.

Data Availability
All data related to this paper may also be requested from the corresponding authors (email: xjsnlhb@fmmu.edu.cn).

Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions
Zhen Li and Lu Zhou contributed equally to this work. Zhen Li performed the animal and cell experiments. Hongbao Liu and Lu Zhou designed the study, obtained research funding, and drafted the manuscript. Yiwei Du and Huirong Li contributed to data collection and analysis. Lan Feng, Xiangnan Li, and Xiao Han revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by grants from the Natural Science Basic Research Plan in Shaanxi Province of China (grant number 2019JM-033) and the Subject Platform and Technology Innovation Development Foundation of Tangdu Hospital (grant numbers 2019QYTS003, 2020XKPT014, and 2021QYJC-001).

Supplementary Materials
Supplementary Table 1: number of TUNEL-positive cells in the kidneys of mice in various treatment groups. (Supplementary Materials)

References
[1] X. Hu, Z. Ma, L. Wen, S. Li, and Z. Dong, “Autophagy in cisplatin nephrotoxicity during cancer therapy,” Cancers (Basel), vol. 13, no. 22, p. 5618, 2021.
[2] S. Sears and L. Siskind, “Potential therapeutic targets for cisplatin-induced kidney injury: lessons from other models of AKI and fibrosis,” Journal of the American Society of Nephrology, vol. 32, no. 7, pp. 1559–1567, 2021.
[3] J. Xu and D. A. Gewirtz, “Is autophagy always a barrier to cisplatin therapy?,” Biomolecules, vol. 12, no. 3, p. 463, 2022.
[4] L. Zhou, P. Yu, T. T. Wang et al., “Polydatin attenuates cisplatin-induced acute kidney injury by inhibiting ferroptosis,” Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 9947191, 14 pages, 2022.
[5] Z. Deng, M. Sun, J. Wu et al., “SIRT1 attenuates sepsis-induced acute kidney injury via Beclin1 deacetylation-mediated autophagy activation,” *Cell Death & Disease*, vol. 12, no. 2, p. 217, 2021.

[6] Y. Gao, X. Dai, Y. Li et al., “Role of Parkin-mediated mitophagy in the protective effect of polydatin in sepsis-induced acute kidney injury,” *Journal of Translational Medicine*, vol. 18, no. 1, p. 114, 2020.

[7] L. Gu, J. Liu, D. Xu, and Y. Lu, “Polydatin prevents LPS-induced acute kidney injury through inhibiting inflammatory and oxidative responses,” *Microbial Pathogenesis*, vol. 137, article 103688, 2019.

[8] S. Xu, Z. Zeng, M. Zhao et al., “Evidence for SIRT1 mediated HMGB1 release from kidney cells in the early stages of hemorrhagic shock,” *Frontiers in Physiology*, vol. 10, p. 854, 2019.

[9] Q. H. Meng, H. B. Liu, and J. B. Wang, “Polydatin ameliorates renal ischemia/reperfusion injury by decreasing apoptosis and oxidative stress through activating sonic hedgehog signaling pathway,” *Food and Chemical Toxicology*, vol. 96, pp. 215–225, 2016.

[10] Z. Zeng, Z. Chen, S. Xu et al., “Polydatin protecting kidneys against hemorrhagic shock-induced mitochondrial dysfunction via SIRT1 activation and p53 deacetylation,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 1737185, 15 pages, 2016.

[11] H. B. Liu, Q. H. Meng, C. Huang, J. B. Wang, and X. W. Liu, “Nephroprotective effects of polydatin against ischemia/reperfusion injury: a role for the PI3K/Akt signal pathway,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 362158, 13 pages, 2015.

[12] Y. Gao, Z. Zeng, T. Li et al., “Polydatin inhibits mitochondrial dysfunction in the renal tubular epithelial cells of a rat model of sepsis-induced acute kidney injury,” *Anesthesia and Analgesia*, vol. 121, no. 5, pp. 1251–1260, 2015.

[13] T. H. Bang, B. S. Park, H. M. Kang, J. H. Kim, and I. R. Kim, “Polydatin, a glycoside of resveratrol, induces apoptosis and inhibits metastasis oral squamous cell carcinoma cells in vitro,” *Pharmaceuticals (Basel)*, vol. 14, no. 9, p. 902, 2021.

[14] A. Luce, S. Lama, P. C. Millan et al., “Polydatin induces differentiation and radiation sensitivity in human osteosarcoma cells and parallel secretion through lipid metabolite secretion,” *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 3337013, 11 pages, 2021.

[15] D. Tang, Q. Zhang, H. Duan et al., “Polydatin: a critical promising natural agent for liver protection via antioxidative stress,” *Oxidative Medicine and Cellular Longevity*, vol. 2022, Article ID 9218738, 14 pages, 2022.

[16] M. C. Pace, M. B. Passavanti, C. Aurilio et al., “Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study,” *In Vivo*, vol. 29, no. 3, pp. 405–408, 2015.

[17] C. Cremon, V. Stanghellini, M. R. Barbaro et al., “Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylthanolamide and polydatin in irritable bowel syndrome,” *Alimentary Pharmacology & Therapeutics*, vol. 45, no. 7, pp. 909–922, 2017.

[18] M. Cervigni, L. Nasta, C. Schievano, N. Lampropoulou, and E. Ostardo, “Micronized palmitoylthanolamide-polydatin reduces the painful symptomatology in patients with interstitial cystitis/bladder pain syndrome,” *BioMed Research International*, vol. 2019, Article ID 9828397, 6 pages, 2019.

[19] X. Yuan, G. Chen, D. Guo, L. Xu, and Y. Gu, “Polydatin alleviates septic myocardial injury by promoting SIRT6-mediated autophagy,” *Inflammation*, vol. 43, no. 3, pp. 785–795, 2020.

[20] T. Li, Y. Liu, W. Xu et al., “Polydatin mediates Parkin-dependent mitophagy and protects against mitochondria-dependent apoptosis in acute respiratory distress syndrome,” *Laboratory Investigation*, vol. 99, no. 6, pp. 819–829, 2019.

[21] Z. Sun and X. Wang, “Protective effects of polydatin on multiple organ ischemia-reperfusion injury,” *Bioorganic Chemistry*, vol. 94, article 103485, 2020.

[22] J. Dai, J. Ma, Y. Liao, X. Luo, and G. Chen, “Polydatin protects H9c2 cells from hypoxia-induced injury via up-regulating long non-coding RNA DGC5,” *Brazilian Journal of Medical and Biological Research*, vol. 52, no. 12, article e8834, 2019.

[23] Y. Ling, G. Chen, Y. Deng et al., “Polydatin post-treatment alleviates myocardial ischemia/reperfusion injury by promoting autophagic flux,” *Clinical Science (London, England)*, vol. 130, no. 18, pp. 1641–1653, 2016.

[24] M. Zhang, S. Wang, Z. Cheng et al., “Polydatin ameliorates diabetic cardiomyopathy via Sirt3 activation,” *Biochemical and Biophysical Research Communications*, vol. 493, no. 3, pp. 1280–1287, 2017.

[25] T. T. Gu, D. M. Zhang, Z. Y. Wan et al., “Polydatin enhances glomerular podocyte autophagy homeostasis by improving Nrf2-dependent antioxidants capacity in fructose-fed rats,” *Molecular and Cellular Endocrinology*, vol. 520, article 111079, 2021.

[26] Q. Xiong, Z. Yan, J. Liang et al., “Polydatin alleviates high-fat diet induced atherosclerosis in apolipoprotein E-deficient mice by autophagic restoration,” *Phytomedicine*, vol. 81, article 153301, 2021.

[27] H. Bai, Y. Ding, X. Li et al., “Polydatin protects SH-SY5Y in models of Parkinson’s disease by promoting Atg5-mediated but Parkin-independent autophagy,” *Neurochemistry International*, vol. 134, article 104671, 2020.

[28] C. Q. Jiang, L. L. Ma, Z. D. Lv, F. Feng, Z. Chen, and Z. D. Liu, “Polydatin induces apoptosis and autophagy via STAT3 signaling in human osteosarcoma MG-63 cells,” *Journal of Natural Medicines*, vol. 74, no. 3, pp. 533–544, 2020.

[29] L. Mele, M. la Noce, F. Paino et al., “Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation,” *Journal of Experimental & Clinical Cancer Research*, vol. 38, no. 1, p. 160, 2019.

[30] B. Yang and S. Zhao, “Polydatin regulates proliferation, apoptosis and autophagy in multiple myeloma cells through mTOR/p70s6k pathway,” *Oncotargets and Therapy*, vol. - Volume 10, pp. 935–944, 2017.

[31] X. Li, L. Liu, T. Li et al., “SIRT6 in senescence and aging-related cardiovascular diseases,” *Frontiers in Cell and Development Biology*, vol. 9, article 641315, 2021.

[32] Z. Li, K. Xu, N. Zhang et al., “Overexpressed SIRT6 attenuates cisplatin-induced acute kidney injury by inhibiting ERK1/2 signaling,” *Kidney International*, vol. 93, no. 4, pp. 881–892, 2018.

[33] J. Liu, M. J. Livingston, G. Dong et al., “Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells,” *Cell Death & Disease*, vol. 9, no. 3, p. 322, 2018.

[34] J. Yang, Y. Li, Y. Zhang et al., “Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by...
mediating PI3K/Akt signaling,” Journal of Experimental & Clinical Cancer Research, vol. 39, no. 1, p. 142, 2020.

[35] S. R. Yoshii and N. Mizushima, “Monitoring and Measuring Autophagy,” International Journal of Molecular Sciences, vol. 18, no. 9, p. 1865, 2017.

[36] G. P. Kaushal and S. V. Shah, “Autophagy in acute kidney injury,” Kidney International, vol. 89, no. 4, pp. 779–791, 2016.

[37] M. Jiang, Q. Wei, G. Dong, M. Komatsu, Y. Su, and Z. Dong, “Autophagy in proximal tubules protects against acute kidney injury,” Kidney International, vol. 82, no. 12, pp. 1271–1283, 2012.

[38] S. M. Sears, T. V. Dupre, P. P. Shah et al., “Neutral ceramidase deficiency protects against cisplatin-induced acute kidney injury,” Journal of Lipid Research, vol. 63, no. 3, article 100179, 2022.

[39] X. Li, L. Liu, W. Jiang et al., “SIRT6 protects against myocardial ischemia-reperfusion injury by attenuating aging-related CHMP2B accumulation,” Journal of Cardiovascular Translational Research, 2022.

[40] Y. Zi, Y. Yi-An, J. Bing et al., “Sirt6-induced autophagy restricted TREM-1-mediated pyroptosis in ox-LDL-treated endothelial cells: relevance to prognostication of patients with acute myocardial infarction,” Cell Death Discov, vol. 5, no. 1, p. 88, 2019.

[41] S. Zhang, S. Jiang, H. Wang et al., “SIRT6 protects against hepatic ischemia-reperfusion injury by inhibiting apoptosis and autophagy related cell death,” Free Radical Biology & Medicine, vol. 115, pp. 18–30, 2018.

[42] Y. Zhao, X. Jia, X. Yang et al., “Deacetylation of Caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation,” Metabolism, vol. 131, article 155162, 2022.

[43] J. Tong, B. Ji, Y. H. Gao et al., “Sirt6 regulates autophagy in AGE-treated endothelial cells via KLF4,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 32, no. 3, pp. 755–764, 2022.

[44] Y. Li, M. Liu, X. Song et al., “Exogenous hydrogen sulfide ameliorates diabetic myocardial fibrosis by inhibiting cell aging through SIRT6/AMPK autophagy,” Frontiers in Pharmacology, vol. 11, p. 1150, 2020.

[45] M. Liu, K. Liang, J. Zhen et al., “Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling,” Nature Communications, vol. 8, no. 1, p. 413, 2017.

[46] Q. L. Wang, L. Yang, Z. L. Liu et al., “Sirtuin 6 regulates macrophage polarization to alleviate sepsis-induced acute respiratory distress syndrome via dual mechanisms dependent on and independent of autophagy,” Cytotherapy, vol. 24, no. 2, pp. 149–160, 2022.

[47] Y. Zhang, L. Wang, L. Meng, G. Cao, and Y. Wu, “Sirtuin 6 overexpression relieves sepsis-induced acute kidney injury by promoting autophagy,” Cell Cycle, vol. 18, no. 4, pp. 425–436, 2019.

[48] J. Guo, Z. Wang, J. Wu et al., “Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling,” Circulation Research, vol. 124, no. 10, pp. 1448–1461, 2019.

[49] K. Y. So, B. H. Park, and S. H. Oh, “Cytoplasmic sirtuin 6 translocation mediated by p62 polyubiquitination plays a critical role in cadmium-induced kidney toxicity,” Cell Biology and Toxicology, vol. 37, no. 2, pp. 193–207, 2021.